Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)Yuankai Shi, Lin Wang, Zhehai Wang et al.|Journal of Thoracic Oncology|2024Cited by 40
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Jason Yang, Ziping Wang et al.|Nature Cancer|2023Cited by 34